LONDON--(BUSINESS WIRE)--Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) announced today that on Monday March 13, 2017, it filed its annual report (“Annual Report”) on Form 20-F with the U.S. Securities and Exchange Commission (“SEC”). On the same day, Chi-Med also released its financial results (“Earnings Release”) for the year ended December 31, 2016 on an announcement filed with the SEC on Form 6-K, which contained the following:
Hutchison China MediTech Limited (“Chi-Med”) Reports Final Results for the Year Ended December 31, 2016 and Updates Shareholders on Key Clinical Programs
Group: Record revenue, net income and clinical investment in 2016
• Group revenue up 21% to $216.1 million (2015: $178.2m);
• Net income attributable to Chi-Med up 46% to $11.7 million (2015: $8.0m), including $76.1 million in research and development expenses on an as adjusted basis (2015: $55.8m).
